Dogwood Therapeutics (DWTX) Non-Current Assets (2024 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Non-Current Assets of $80.2 million for Q1 2026, up 3.06% year-over-year from $77.8 million in Q1 2025, and down 1.88% quarter-over-quarter from $81.7 million in Q4 2025.
Dogwood Therapeutics (DWTX) Non-Current Assets (2024 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Non-Current Assets for 3 consecutive years, with $80.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 3.06% year-over-year to $80.2 million; the TTM figure through Mar 2026 stood at $324.3 million (up 108.42% YoY), while the FY2025 annual figure was $81.7 million, up 5.11% from the prior year.
- Non-Current Assets retreated to $80.2 million in Q1 2026 per DWTX's latest filing, from $81.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $82.0 million in Q2 2025 and bottomed at $77.8 million in Q4 2024.
- Historically, Non-Current Assets has averaged $80.0 million across 3 years, with a median of $80.3 million in 2025.
- Annual changes were most pronounced in 2025 — Non-Current Assets grew 5.11% — and 2026, when it climbed 3.06%.
- Dogwood Therapeutics' Non-Current Assets stood at $77.8 million in 2024, then climbed by 5.11% to $81.7 million in 2025, then declined by 1.88% to $80.2 million in 2026.
- Business Quant data shows DWTX's Non-Current Assets at $80.2 million in Q1 2026, $81.7 million in Q4 2025, and $80.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 69.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.20 Mn |
| Dec 31, 2025 | 81.74 Mn |
| Sep 30, 2025 | 80.34 Mn |
| Jun 30, 2025 | 81.99 Mn |
| Mar 31, 2025 | 77.82 Mn |
| Dec 31, 2024 | 77.76 Mn |